Navigation Links
Oncothyreon files investigational new drug application for PX-866 oncology compound
Date:5/1/2008

d single agent in vivo anti-tumor activity and work well in combination with other agents in a number of human tumor models.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to future clinical development plans for PX-866. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-866. There can be no guarantee that the results of preclinical studies or of early clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other do
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
2. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
3. Oncothyreon announces effectiveness of shelf registration statement
4. Oncothyreon announces issuance of patent for PX-867
5. Oncothyreon to present at upcoming investment conferences
6. Oncothyreon reports full year and fourth quarter 2007 financial results
7. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
8. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
9. Oncothyreon launches new corporate website
10. Oncothyreon to present at BIO CEO & Investor Conference
11. Oncothyreon highlights corporate and clinical objectives for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Inflamax Research Inc., a full service ... I-IV clinical trials, announced today that they will ... Technologies (NAET), a specialty air conditioning & environmental ... of mobile Environmental Exposure Chambers (EECs) used in ... , Inflamax Research has proprietary Next Generation ...
(Date:6/18/2013)... Woburn, MA (PRWEB) June 18, 2013 ... of an automated system for rapid bacterial strain ... M.B.A., has joined the company as Vice President ... and integration for the company’s RESOLUTION™ Microbial ... which includes the benchtop instrument, pathogen-specific assay kits, ...
(Date:6/18/2013)... Pensacola, FL (PRWEB) June 18, 2013 ... sleep/wake monitoring solutions for the global research community, announced ... Scientific Advisory Board. Dr. Matsudo is the Scientific Director ... do Sul (CELAFISCS), a Professor of Medicine at Gama ... Paulo Program, organized by the State Secretariat of Health ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 NuView Life ... imaging and in vitro diagnostic (IVD) biomarkers, today announced ... novel urine screen in development for the early detection ... presented in an oral presentation at the 2013 Annual ... Imaging (SNMMI) in Vancouver, Canada on Sunday, June 9th. ...
Breaking Biology Technology:Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System 2PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System 3Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board 2NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 2NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 3
... Jan. 23, 2012 Novus International Inc., a leading ... and Verenium Corporation (Nasdaq: VRNM ), a ... commercialization of high-performance enzymes, today announced the selection of ... the two companies, strategic collaboration to advance ...
...   NeoStem, Inc. (NYSE Amex: NBS ) ... focus on cell-based therapeutic development, today announced that its Chief ... 2 clinical trial for AMR-001 for preservation of heart ... of its subsidiary, Progenitor Cell Therapy, LLC , have ...
... Jan. 23, 2012   BioLife Solutions , Inc. (OTCBB: ... hypothermic storage and cryopreservation freeze ... three additional key opinion leaders in the biobanking ... markets have joined the Company,s Scientific Advisory ...
Cached Biology Technology:First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 2First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 3First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 4First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 5Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 2Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 3Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 4BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 2BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 3BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 4BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board 5
(Date:6/17/2013)... JOLLA, CA June 17, 2013 An international ... (TSRI), the Howard Hughes Medical Institute and Albert Einstein ... highly promising new anti-tuberculosis compound that attacks the tuberculosis ... represent an effort to help solve one of the ... TB and its dangerous drug-resistant strains," said Peter G. ...
(Date:6/17/2013)... 17, 2013 As mobile devices, smartphones ... secure them grows exponentially, and biometric authentication offers ... Heavy Reading Insider ( www.heavyreading.com/mobile-networks ), ... ( www.heavyreading.com ). Biometrics Offer ... for biometric authentication on smartphones, analyzing the most ...
(Date:6/17/2013)... and Entrepreneurship will be the topics under discussion ... June. For the third consecutive year, this will ... sharing of experiences among members of Academy, Business, ... students. Confirmed speakers: Elisa Martn Garijo (IBM South ... Tree) and Mary O,Donovan (Hovione), among others. E3 ...
Breaking Biology News(10 mins):New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4Biometric Authentication Provides Better Mobile Device Security, Heavy Reading Finds 2Biometric Authentication Provides Better Mobile Device Security, Heavy Reading Finds 3'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2
... functions is largely based on our family,s genetic makeup, according ... published in the international publication the Journal of Neuroscience ... how ,cost-efficient, our brain network wiring is, shedding light on ... Alex Fornito from the Melbourne Neuropsychiatry Centre at the University ...
... the important first rung of the food web each spring ... to its advantage, according to the first published findings about ... algae as a kind of antifreeze against temperatures well below ... channels and pores in ice that are hospitable to itself ...
... bugs, originally from Asia, were first detected in Pennsylvania ... and vegetables and invading homes in many parts of ... entomologists from the eastern U.S. and Canada will converge ... brown marmorated stink bug plague during the 82nd Annual ...
Cached Biology News:Better brain wiring linked to family genes 2Algal antifreeze makes inroads into ice 2Stink bug experts gather in Pennsylvania to address growing problem 2
Rabbit polyclonal to Staphylococcus Enterotoxin A (HRP) ( Abpromise for all tested applications)....
... Novexin offers bespoke, cost-effective solutions for complex protein processing ... expertise and experience to help you develop a solution ... , ... transfer all methodology to ...
... is a highly scalable analysis platform ... in a workgroup or an enterprise ... 40 leading pharmaceutical, biotechnology, academic and ... streamlines genomics research at large and ...
... LC Sciences provides a genome-wide microRNA ... and proprietary probe design, which enable highly ... (1-3). We have standard arrays for mature ... latest version of the Sanger miRBase database ...
Biology Products: